IL-27R alpha/TCCR Protein, Human (514a.a, HEK293, Fc)

IL-27R alpha(Interleukin 27 receptor alpha) is a subunit of the interleukin-27 receptor, an inflammatory cytokine that possesses extensive immunological functions. IL-27R alphacan be used as a natural IL-27 antagonist^[1]. IL-27R alpha/TCCR Protein, Human (514a.a, HEK293, Fc) is a recombinant protein with a Fc label that consists of 514 amino acids (M1-R514) and is produced by HEK293 cells.

IL-27Rα is specific for IL-27 and is primarily expressed on the cell surface of inflammatory cells, including T, B, and NK lymphocytes, neutrophils, monocytes, and mast cells, although it is found at lower levels in macrophages, hepatocytes, keratinocytes, and endothelial cells^[2].
The amino acid sequence of human IL-27R alpha protein has low homology for mouse IL-27R alpha protein.
IL-27Rα (WSX-1) and gp130 compose the IL-27 receptor-signaling complex. Binding of IL-27 to its heterodimeric receptor complex leads to the intracellular recruitment and activation of the Janus kinase (JAK)/STAT-1 and STAT-3 pathways, suppress the expression of inflammatory cytokines^[3].
IL-27R alpha is a class I cytokine receptor with homology to gp130 of IL-6R and to IL-12R families. IL-27R alpha can be used as a natural IL-27 antagonist^[1]. IL-27R alpha can be used as an independent prognostic aGVHD biomarker^[4]. IL-27/IL-27R alpha also plays an important role in the down-regulation of airway hyper-reactivity and lung inflammation during the development of allergic asthma through its suppressive effect on cytokine production^[5]. IL-27/IL-27RA signaling can suppress the expression of inflammatory cytokines, IL-6 and IL-8, induced by LPS stimulation, leading to phosphorylation of STAT1 and STAT3^[6].

Human

HEK293

C-hFc

Q6UWB1 (Q33-R514)

9466  [NCBI]

105-115 kDa

Greater than 95% as determined by reducing SDS-PAGE

<1 EU/μg, determined by LAL method.

• [1]. Liu S, et al. Soluble interleukin-27 receptor alpha is a valuable prognostic biomarker for acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Sci Rep. 2018 Jul 9;8(1):10328.  [Content Brief]

  [2]. Fabbi M, et al. Dual Roles of IL-27 in Cancer Biology and Immunotherapy. Mediators Inflamm. 2017;2017:3958069.  [Content Brief]

  [3]. Rousseau F, et al. IL-27 structural analysis demonstrates similarities with ciliary neurotrophic factor (CNTF) and leads to the identification of antagonistic variants. Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19420-5.  [Content Brief]

  [4]. Miyazaki Y, et al. Exacerbation of experimental allergic asthma by augmented Th2 responses in WSX-1-deficient mice. J Immunol. 2005 Aug 15;175(4):2401-7.  [Content Brief]

  [5]. Lo HC, et al. IL-27/IL-27RA signaling may modulate inflammation and progression of benign prostatic hyperplasia via suppressing the LPS/TLR4 pathway. Transl Cancer Res. 2020 Aug;9(8):4618-4634.  [Content Brief]